Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized trial of Picankibart (IBI112) in active psoriatic arthritis
ChiCTR2500112012Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of picankibart in psoriatic arthritis (PsA) (5 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: ACR20 response at Week 26. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
picankibart
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ChiCTR2500112012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112012.